Señales en vivo de FARN.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 07:49):

Stats
Volumen de hoy	4 213.00
Volumen promedio	32 249.00
Capitalización de mercado	108.01M
EPS	£0 ( 2024-03-13 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-3.66
ATR14	£0 (0.00%)

Faron Pharmaceuticals Oy Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Faron Pharmaceuticals Oy Finanzas

Annual	2023
Ingresos:	£0
Beneficio Bruto:	£0 (0.00 %)
EPS:	£-0.480

FY	2023
Ingresos:	£0
Beneficio Bruto:	£0 (0.00 %)
EPS:	£-0.480

FY	2022
Ingresos:	£0
Beneficio Bruto:	£0 (0.00 %)
EPS:	£-0.590

FY	2021
Ingresos:	£0.00
Beneficio Bruto:	£0.00 (0.00 %)
EPS:	£-0.420

Financial Reports:

No articles found.

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.